CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Ignacio Melero 1 2 3 4 , Miguel F Sanmamed 1 2 3 4 , Javier Glez-Vaz 1 2 , Carlos Luri-Rey 1 2 , Jun Wang 5 , Lieping Chen 6
CD137 (4-1BB) is a costimulatory receptor of T and natural killer lymphocytes whose activity can be exploited in cancer immunotherapy strategies as discovered 25 years ago.
Following initial attempts that met unacceptable toxicity, new waves of constructs acting agonistically on CD137 are being developed in patients, offering signs of clinical and pharmacodynamic activity with tolerable safety profiles.
CITA DEL ARTÍCULO Cancer Discov. 2023 Mar 1;13(3):552-569. doi: 10.1158/2159-8290.CD-22-1029